EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Assessing risk of lymph node invasion in complete responders to neoadjuvant chemotherapy for muscle‐invasive bladder cancer

Rocco Simone Flammia iD, Gabriele Tuderti, Eugenio Bologna, Antonio Minore iD, Flavia Proietti, Leslie Claire Licari, Riccardo Mastroianni, Umberto Anceschi, Aldo Brassetti, Alfredo Bove, Leonardo Misuraca, Simone D'Annunzio und 6 weitere

BJU International · 2024-12 · 134 (6) · 976-981

DOI: 10.1111/bju.16440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, online erschienen am 24.06.2024. Verfasst von Rocco Simone Flammia und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Neoadjuvant Therapy, Lymphatic Metastasis, Cystectomy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the lymph node invasion (LNI) rate in patients exhibiting complete pathological response (CR) to neoadjuvant chemotherapy (NAC) and to test the association of CR status with lower LNI and better survival outcomes. Materials and Methods We included patients with bladder cancer (BCa; cT2‐4a; cN0; cM0) treated with NAC and radical cystectomy (RC) + pelvic lymph node dissection (PLND) at our institution between 2012 and 2022 ( N = 157). CR (ypT0) and LNI (ypN+) were defined at final pathology. Univariable and multivariable logistic regression analysis was performed to test the association between CR and LNI after adjusting for number of lymph nodes removed (NLR). Kaplan–Meier and Cox regression analyses were used to assess overall survival (OS), metastasis‐free survival (MFS) and disease free‐survival (DFS) according to CR status.

Results

Overall CR and LNI rates were 40.1% and 19%, respectively. The median (interquartile range [IQR]) NLR was 26 (19–36). The LNI rate was lower in patients with CR vs those without CR (2 [3.2%] vs 61 [29.8%]; P < 0.001). After adjusting for NLR, CR reduced the LNI risk by 93% (odds ratio 0.07, 95% confidence interval [CI] 0.01–0.25; P < 0.001). Kaplan–Meier plots depicted better 5‐year OS (69.7 vs 52.2%), MFS (68.3 vs 45.5%) and DFS (66.6 vs 43.5%) in patients with CR vs those without CR. After multivariable adjustments, CR independently reduced the risk of death (hazard ratio [HR] 0.44, 95% CI 0.24–0.81; P = 0.008), metastatic progression (HR 0.41, 95% CI 0.23–0.71; P = 0.002) and disease progression (HR 0.41, 95% CI 0.24–0.70; P = 0.001).

Conclusion

Based on these findings, we postulate that PLND could potentially be omitted in patients exhibiting CR after NAC, due to negligible risk of LNI. Prospective Phase II trials are needed to explore this challenging hypothesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsNeoadjuvant TherapyLymphatic MetastasisCystectomyNeoplasm InvasivenessHumansMaleFemaleAgedMiddle AgedLymph Node ExcisionChemotherapy, AdjuvantRetrospective StudiesLymph NodesRisk AssessmentTreatment Outcome

Stichwörter der Autor:innen

complete responsemuscle‐invasive bladder cancerneoadjuvant chemotherapypelvic lymph node dissectionradical cystectomy

Autor:innen und Institutionen

  • Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.
  • Department of Surgery, Sapienza University of Rome, Rome, Italy.
  • Department of Urology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.

ORCID-Profile: Rocco Simone Flammia, Antonio Minore, Costantino Leonardo, Giuseppe Simone

Zitieren

APA

Flammia, R. S., Tuderti, G., Bologna, E., Minore, A., Proietti, F., Licari, L. C., Mastroianni, R., Anceschi, U., Brassetti, A., Bove, A., Misuraca, L., D'Annunzio, S., Ferriero, M. C., Guaglianone, S., Chiacchio, G., De Nunzio, C., Leonardo, C., & Simone, G. (2024). Assessing risk of lymph node invasion in complete responders to neoadjuvant chemotherapy for muscle‐invasive bladder cancer. BJU International, 134(6), 976-981. https://doi.org/10.1111/bju.16440

Vancouver

Flammia RS, Tuderti G, Bologna E, Minore A, Proietti F, Licari LC, et al. Assessing risk of lymph node invasion in complete responders to neoadjuvant chemotherapy for muscle‐invasive bladder cancer. BJU International. 2024;134(6):976-981. doi:10.1111/bju.16440

BibTeX
@article{Flammia2024,
  author = {Flammia, Rocco Simone and Tuderti, Gabriele and Bologna, Eugenio and Minore, Antonio and Proietti, Flavia and Licari, Leslie Claire and Mastroianni, Riccardo and Anceschi, Umberto and Brassetti, Aldo and Bove, Alfredo and Misuraca, Leonardo and D'Annunzio, Simone and Ferriero, Maria Consiglia and Guaglianone, Salvatore and Chiacchio, Giuseppe and De Nunzio, Cosimo and Leonardo, Costantino and Simone, Giuseppe},
  title = {Assessing risk of lymph node invasion in complete responders to neoadjuvant chemotherapy for muscle‐invasive bladder cancer},
  journal = {BJU International},
  year = {2024},
  volume = {134},
  number = {6},
  pages = {976--981},
  doi = {10.1111/bju.16440}
}
Kostenlos starten →